WO2022168975A1 - 炎症性疾患及び/又は疼痛性疾患の予防又は治療薬 - Google Patents
炎症性疾患及び/又は疼痛性疾患の予防又は治療薬 Download PDFInfo
- Publication number
- WO2022168975A1 WO2022168975A1 PCT/JP2022/004692 JP2022004692W WO2022168975A1 WO 2022168975 A1 WO2022168975 A1 WO 2022168975A1 JP 2022004692 W JP2022004692 W JP 2022004692W WO 2022168975 A1 WO2022168975 A1 WO 2022168975A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- glutathione trisulfide
- inflammatory
- steroidal anti
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims description 29
- 229940124597 therapeutic agent Drugs 0.000 title claims description 17
- 230000003449 preventive effect Effects 0.000 title abstract description 8
- 208000027753 pain disease Diseases 0.000 title abstract description 4
- 208000027520 Somatoform disease Diseases 0.000 title abstract 2
- 108700026078 glutathione trisulfide Proteins 0.000 claims abstract description 134
- 150000003839 salts Chemical class 0.000 claims abstract description 92
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 87
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 65
- 230000000069 prophylactic effect Effects 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- -1 amino acid salts Chemical class 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 229910052783 alkali metal Inorganic materials 0.000 claims description 11
- 150000001484 arginines Chemical class 0.000 claims description 10
- 159000000000 sodium salts Chemical class 0.000 claims description 10
- 229940043274 prophylactic drug Drugs 0.000 claims description 8
- 229940126585 therapeutic drug Drugs 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 9
- 229960001860 salicylate Drugs 0.000 description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229960000905 indomethacin Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present invention relates to preventive or therapeutic agents for inflammatory diseases and/or painful diseases.
- Non-Steroidal Anti-Inflammatory Drugs inhibit cyclooxygenase (COX), a prostaglandin synthase, to exert anti-inflammatory, antipyretic, analgesic, and anticoagulant effects. It is a drug that exerts its effects and is widely used for medical treatment (for example, Patent Document 1).
- GSSSG glutathione trisulfide
- active sulfur molecular species such as oxidized glutathione (GSSH). It has been reported that active sulfur molecular species have a strong antioxidant effect and may have physiological functions such as anti-aging (for example, Non-Patent Documents 1 and 2).
- the purpose of the present invention is to provide prophylactic or therapeutic drugs for inflammatory diseases and/or painful diseases that have high prophylactic or therapeutic effects.
- the present inventors have found that administration of a combination of a non-steroidal anti-inflammatory drug and glutathione trisulfide shows a high preventive or therapeutic effect on inflammatory diseases and/or painful diseases, and completed the present invention. let me
- the present invention provides the following [1] to [46].
- [3] glutathione trisulfide or a pharmaceutically acceptable salt thereof and a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof are administered simultaneously or separately, [1] or [ 2], the prophylactic or therapeutic drug according to [4] Prevention of inflammatory diseases and/or painful diseases containing glutathione trisulfide or a pharmaceutically acceptable salt thereof and a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof, or remedy.
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, amino acid salts of glutathione trisulfide and alkali metal salts of glutathione trisulfide, [ 1] to the preventive or therapeutic agent according to any one of [4].
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [1 ] to [4], the preventive or therapeutic agent according to any one of [7]
- the nonsteroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate nonsteroidal antiinflammatory drug, a propionate nonsteroidal antiinflammatory drug, and an acetic acid nonsteroidal antiinflammatory drug
- Inflammatory diseases including formulations containing glutathione trisulfide or a pharmaceutically acceptable salt thereof, and formulations containing a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof, and / Or a kit for the prevention or treatment of painful diseases.
- a formulation containing glutathione trisulfide or a pharmaceutically acceptable salt thereof and a formulation containing a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof are administered simultaneously or separately.
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [8 ] or the kit according to [9].
- the non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate non-steroidal anti-inflammatory drug, a propionate non-steroidal anti-inflammatory drug and an acetic acid non-steroidal anti-inflammatory drug
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, amino acid salts of glutathione trisulfide and alkali metal salts of glutathione trisulfide, [ 13] or the method according to [14].
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [13 ] or the method according to [14].
- the non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate non-steroidal anti-inflammatory drug, a propionate non-steroidal anti-inflammatory drug and an acetic acid non-steroidal anti-inflammatory drug The method according to any one of [13] to [16], including at least one selected from the group.
- a non-steroidal anti-inflammatory drug for use in the prevention or treatment of inflammatory and/or painful diseases characterized by being administered in combination with glutathione trisulfide or a pharmaceutically acceptable salt thereof.
- An inflammatory drug or a pharmaceutically acceptable salt thereof An inflammatory drug or a pharmaceutically acceptable salt thereof.
- glutathione trisulfide or a pharmaceutically acceptable salt thereof and a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof are administered simultaneously or separately.
- a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof for use in [20] glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, amino acid salts of glutathione trisulfide and alkali metal salts of glutathione trisulfide, [ 18] or a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof for use according to [19].
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [18 ] or a non-steroidal anti-inflammatory drug for use according to [19] or a pharmaceutically acceptable salt thereof.
- the nonsteroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate nonsteroidal antiinflammatory drug, a propionate nonsteroidal antiinflammatory drug, and an acetic acid nonsteroidal antiinflammatory drug
- Glutathione for use in the prevention or treatment of inflammatory diseases and/or painful diseases characterized by being administered in combination with a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof A trisulfide or a pharmaceutically acceptable salt thereof.
- Glutathione trisulfide or a pharmaceutically acceptable salt thereof for use in [25] glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, amino acid salts of glutathione trisulfide and alkali metal salts of glutathione trisulfide, [ 23] or glutathione trisulfide or a pharmaceutically acceptable salt thereof for use according to [24].
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [23 ] or glutathione trisulfide or a pharmaceutically acceptable salt thereof for use according to [24].
- the nonsteroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate nonsteroidal antiinflammatory drug, a propionate nonsteroidal antiinflammatory drug, and an acetic acid nonsteroidal antiinflammatory drug Glutathione trisulfide or a pharmaceutically acceptable salt thereof for use according to any one of [23] to [26], including at least one selected from the group.
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, an amino acid salt of glutathione trisulfide and an alkali metal salt of glutathione trisulfide, [ 28] or a combination for use according to [29].
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [28 ] or a combination for use according to [29].
- the nonsteroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate nonsteroidal antiinflammatory drug, a propionate nonsteroidal antiinflammatory drug, and an acetic acid nonsteroidal antiinflammatory drug The combination for use according to any one of [28] to [31], comprising at least one selected from the group.
- a non-steroidal compound for the production of a prophylactic or therapeutic drug for inflammatory diseases and/or painful diseases characterized by being administered in combination with glutathione trisulfide or a pharmaceutically acceptable salt thereof Use of an anti-inflammatory agent or a pharmaceutically acceptable salt thereof.
- glutathione trisulfide or a pharmaceutically acceptable salt thereof and a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof are administered simultaneously or separately. Use of.
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, amino acid salts of glutathione trisulfide and alkali metal salts of glutathione trisulfide, [ 33] or use according to [34].
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [33 ] or use according to [34].
- the nonsteroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate nonsteroidal antiinflammatory drug, a propionate nonsteroidal antiinflammatory drug, and an acetic acid nonsteroidal antiinflammatory drug
- [38] For the production of a prophylactic or therapeutic drug for inflammatory diseases and/or painful diseases, characterized by being administered in combination with a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof Use of glutathione trisulfide or a pharmaceutically acceptable salt thereof.
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, amino acid salts of glutathione trisulfide and alkali metal salts of glutathione trisulfide, [ 38] or use according to [39].
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [38 ] or use according to [39].
- the non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate non-steroidal anti-inflammatory drug, a propionate non-steroidal anti-inflammatory drug and an acetate non-steroidal anti-inflammatory drug The use according to any one of [38] to [41], including at least one selected from the group.
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, amino acid salts of glutathione trisulfide and alkali metal salts of glutathione trisulfide, [ 43].
- glutathione trisulfide or a pharmaceutically acceptable salt thereof comprises at least one selected from the group consisting of glutathione trisulfide, arginine salt of glutathione trisulfide and sodium salt of glutathione trisulfide, [43 ].
- the non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof consists of a salicylate non-steroidal anti-inflammatory drug, a propionate non-steroidal anti-inflammatory drug and an acetic acid non-steroidal anti-inflammatory drug The use according to any one of [43] to [45], including at least one selected from the group.
- prophylactic or therapeutic agents for inflammatory diseases and/or painful diseases that have high prophylactic or therapeutic effects.
- FIG. 1 is a graph showing changes in hind limb volume in adjuvant arthritis model rats when indomethacin and glutathione trisulfide were administered alone and in combination.
- the prophylactic or therapeutic agent and prophylactic or therapeutic method of the present invention may be administered or applied to humans.
- an inflammatory disease refers to a disease whose etiology is inflammation.
- the prophylactic or therapeutic agent and the prophylactic or therapeutic method of the present invention can be used not only for inflammatory diseases, but also for pain diseases in which pain is one of the symptoms, and thrombotic diseases in which thrombus formation is one of the etiologies. is considered to have a high prophylactic or therapeutic effect.
- inflammatory diseases include, for example, systemic lupus erythematosus, scleroderma, atopic dermatitis, contact dermatitis, psoriasis, rheumatoid arthritis, osteoarthritis, interstitial pneumonia, bronchial asthma, Airway inflammation, tonsillitis, chronic obstructive pulmonary disease, pulmonary hypertension, inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease, nerve injury, spinal cord injury, spinal canal stenosis, stroke (cerebral infarction and cerebral hemorrhage) sequelae), amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, Parkinson's disease, dementia such as Alzheimer's disease and vascular dementia, schizophrenia, organ transplantation Rejection, acute kidney injury, diabetic renal failure, lupus nephritis, pyelonephritis, IgA ne
- IBD
- salts include, for example, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid , citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, salts with organic acids such as p-toluenesulfonic acid; salts with alkali metals such as sodium and potassium; alkalis such as calcium and magnesium salts with earth metals; ammonium salts; salts with amino acids such as arginine;
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid
- acetic acid succinic acid, fumaric acid, maleic acid, tartaric acid , citric acid, lactic acid, stearic acid, benzoic acid, methane
- Non-steroidal anti-inflammatory drugs include, for example, salicylates such as acetylsalicylic acid; propionic acids such as ibuprofen, loxoprofen, naproxen, ketoprofen and flurbiprofen; acetates such as indomethacin and diclofenac; celecoxib and rofecoxib.
- aniline NSAIDs such as acetaminophen, mefenamic acid and tolfenamic acid;
- Glutathione trisulfide can increase glutathione levels in the body, and since glutathione has a strong antioxidant effect, increased levels of glutathione in the body effectively remove peroxides and reactive oxygen species. It can protect cells.
- administration in combination means the use of active ingredients in combination, and (1) mode of administration as a single formulation containing NSAIDs and GSSSG and (2) NSAIDs and GSSSG are administered simultaneously or separately with a time lag as separate formulations.
- NSAIDs may be administered first, or GSSSG may be administered first.
- GSSSG may be administered first.
- NSAIDs and GSSSG are separately formulated and administered simultaneously via the same administration route, (ii) NSAIDs and GSSSG are formulated separately and are administered at different times via the same administration route.
- NSAIDs and GSSSG are formulated separately and administered simultaneously by different routes of administration (administered from different sites in the same patient),
- NSAIDs and GSSSG are formulated separately Alternatively, they may be administered separately with different administration routes at different times. In the case of (i), both drugs may be mixed immediately before administration.
- administered in combination means that the action/effect (anti-inflammatory action, analgesic action, anticoagulant action, etc.) of one of the drugs is manifested in the body of the patient. It can also be said to be a mode of use in which the other drug is administered in a state where the other drug is administered. That is, in the present invention, it is preferable to administer NSAIDs and GSSSG so that they are present simultaneously in the patient's body, for example, in the blood. A mode of administering a drug is preferred.
- the dose of NSAIDs is preferably 0.1 to 50 mg (0.1 to 50 mg/kg/day), more preferably 0.5 to 20 mg/kg/day, and 1 to 10 mg/kg/day per 1 kg of body weight. day is more preferred.
- the dosage of GSSSG is preferably 0.5 to 1000 mg (0.5 to 1000 mg/kg/day), more preferably 1 to 400 mg/kg/day, and 2 to 200 mg/kg/day per 1 kg of body weight. More preferred.
- the dose of NSAIDs is 0.1 to 50 mg/kg/day and the dose of GSSSG is 0.5 to 1000 mg/kg/day, and the dose of NSAIDs is 0.5 to 20 mg/kg/day and More preferably, the dose of GSSSG is 1-400 mg/kg/day, and even more preferably, the dose of NSAIDs is 1-10 mg/kg/day and the dose of GSSSG is 2-200 mg/kg/day. .
- the doses of NSAIDs and GSSSG are in this range, it is believed that a higher preventive effect against inflammatory diseases and/or pain diseases is exhibited, and a higher therapeutic effect is exhibited. In addition, an effect of further reducing side effects is also expected.
- the administration frequency of NSAIDs and GSSSG can be 1-6 times a day or 1-4 times a day. Such an administration frequency is considered to reduce the patient's burden of taking medication and improve compliance with taking medication. As a result, it is expected that the effects such as anti-inflammatory effects and the effect of reducing side effects achieved by the prophylactic or therapeutic drug of the present invention will be further improved.
- drug administration is discontinued, the dose of the drug may be reduced in stages. For example, there is a method of administering one drug during a drug withdrawal period of the other drug.
- the prophylactic or therapeutic agent for inflammatory diseases and/or painful diseases of the present invention can be administered orally in the form of solid formulations such as tablets, granules, fine granules, powders, capsules, liquid formulations, jelly formulations, syrup formulations, etc. can be administered.
- the prophylactic or therapeutic agent for inflammatory diseases and/or painful diseases of the present invention may be administered parenterally in the form of injections, suppositories, ointments, poultices, sprays, and the like. These dosage forms can be formulated according to known methods.
- the prophylactic or therapeutic drug for inflammatory diseases and/or painful diseases of the present invention is obtained by mixing either or both of the first component and the second component with water, ethanol, physiological saline, liquid paraffin, or the like. you can
- ⁇ Synergistic effect of combined use in rat adjuvant arthritis model Necessary amounts of GSSSG and indomethacin were weighed with an electronic balance, thoroughly ground with a mortar, and suspended in a solvent (0.5% methylcellulose (MC) suspension). The administration solution of GSSSG alone was prepared to have a concentration of 21.2 mg/mL (20 mg/mL on an anhydrous basis), and the administration solution of indomethacin alone was prepared to have a concentration of 0.06 mg/ml or 0.6 mg/mL.
- the combined administration solution was prepared by mixing an equal volume of 0.12 mg/ml and 1.2 mg/mL indomethacin suspensions with a suspension prepared with GSSSG at 42.4 mg/mL (40 mg/mL on an anhydrous basis). .
- the dosing solution was prepared for 2 weeks at a time and stored under refrigeration and light-shielding conditions until administration.
- mice On the day of the end of the acclimation period, the rats were subcutaneously sensitized with 50 ⁇ l of the prepared adjuvant under isoflurane inhalation anesthesia in the right hind leg plantar.
- the administration solution of indomethacin alone, the administration solution of GSSSG alone, and the administration solution of GSSSG alone were administered by forced oral administration at a volume of 5 mL/kg for 14 days from the day of grouping.
- the dose was calculated based on the most recent body weight.
- the volume of the left hindlimb (non-sensitized paw) was measured using a rat hindlimb paw edema volume measuring device (TK-101P; Natsume Seisakusho Co., Ltd.). did.
- the measurement was performed 5 times/animal/day, and the volume was taken as the average value for 3 times excluding the highest and lowest values.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
[1]グルタチオントリスルフィド又はその製剤学的に許容される塩と組み合わせて投与されることを特徴とする、非ステロイド性抗炎症薬又はその製剤学的に許容される塩を含有する炎症性疾患及び/又は疼痛性疾患の予防又は治療薬。
[2]非ステロイド性抗炎症薬又はその製剤学的に許容される塩と組み合わせて投与されることを特徴とする、グルタチオントリスルフィド又はその製剤学的に許容される塩を含有する炎症性疾患及び/又は疼痛性疾患の予防又は治療薬。
[3]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とが、同時に又は別々に投与される、[1]又は[2]に記載の予防又は治療薬。
[4]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とを含有する炎症性疾患及び/又は疼痛性疾患の予防又は治療薬。
[5]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[1]~[4]のいずれかに記載の予防又は治療薬。
[6]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[1]~[4]のいずれかに記載の予防又は治療薬。
[7]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[1]~[6]のいずれかに記載の予防又は治療薬。
[8]グルタチオントリスルフィド又はその製剤学的に許容される塩を含有する製剤と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩を含有する製剤とを含む、炎症性疾患及び/又は疼痛性疾患の予防又は治療用キット。
[9]グルタチオントリスルフィド又はその製剤学的に許容される塩を含有する製剤と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩を含有する製剤とが、同時に又は別々に投与される、[8]に記載のキット。
[10]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[8]又は[9]に記載のキット。
[11]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[8]又は[9]に記載のキット。
[12]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[8]~[11]のいずれかに記載のキット。
[13]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とを、それらを必要とする患者に投与する、炎症性疾患及び/又は疼痛性疾患の予防又は治療方法。
[14]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とが、同時に又は別々に投与される、[13]に記載の方法。
[15]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[13]又は[14]に記載の方法。
[16]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[13]又は[14]に記載の方法。
[17]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[13]~[16]のいずれかに記載の方法。
[18]グルタチオントリスルフィド又はその製剤学的に許容される塩と組み合わせて投与されることを特徴とする、炎症性疾患及び/又は疼痛性疾患の予防又は治療に使用するための非ステロイド性抗炎症薬又はその製剤学的に許容される塩。
[19]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とが、同時に又は別々に投与される、[18]に記載の使用するための非ステロイド性抗炎症薬又はその製剤学的に許容される塩。
[20]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[18]又は[19]に記載の使用するための非ステロイド性抗炎症薬又はその製剤学的に許容される塩。
[21]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[18]又は[19]に記載の使用するための非ステロイド性抗炎症薬又はその製剤学的に許容される塩。
[22]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[18]~[21]のいずれかに記載の使用するための非ステロイド性抗炎症薬又はその製剤学的に許容される塩。
[23]非ステロイド性抗炎症薬又はその製剤学的に許容される塩と組み合わせて投与されることを特徴とする、炎症性疾患及び/又は疼痛性疾患の予防又は治療に使用するためのグルタチオントリスルフィド又はその製剤学的に許容される塩。
[24]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とが、同時に又は別々に投与される、[23]に記載の使用するためのグルタチオントリスルフィド又はその製剤学的に許容される塩。
[25]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[23]又は[24]に記載の使用するためのグルタチオントリスルフィド又はその製剤学的に許容される塩。
[26]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[23]又は[24]に記載の使用するためのグルタチオントリスルフィド又はその製剤学的に許容される塩。
[27]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[23]~[26]のいずれかに記載の使用するためのグルタチオントリスルフィド又はその製剤学的に許容される塩。
[28]炎症性疾患及び/又は疼痛性疾患の予防又は治療に使用するためのグルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩との組み合わせ。
[29]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とが、同時に又は別々に投与される、[28]に記載の使用するための組み合わせ。
[30]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[28]又は[29]に記載の使用するための組み合わせ。
[31]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[28]又は[29]に記載の使用するための組み合わせ。
[32]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[28]~[31]のいずれかに記載の使用するための組み合わせ。
[33]グルタチオントリスルフィド又はその製剤学的に許容される塩と組み合わせて投与されることを特徴とする、炎症性疾患及び/又は疼痛性疾患の予防又は治療薬の製造のための非ステロイド性抗炎症薬又はその製剤学的に許容される塩の使用。
[34]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とが、同時に又は別々に投与される、[33]に記載の使用。
[35]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[33]又は[34]に記載の使用。
[36]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[33]又は[34]に記載の使用。
[37]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[33]~[36]のいずれかに記載の使用。
[38]非ステロイド性抗炎症薬又はその製剤学的に許容される塩と組み合わせて投与されることを特徴とする、炎症性疾患及び/又は疼痛性疾患の予防又は治療薬の製造のためのグルタチオントリスルフィド又はその製剤学的に許容される塩の使用。
[39]グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とが、同時に又は別々に投与される、[38]に記載の使用。
[40]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[38]又は[39]に記載の使用。
[41]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[38]又は[39]に記載の使用。
[42]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[38]~[41]のいずれかに記載の使用。
[43]炎症性疾患及び/又は疼痛性疾患の予防又は治療薬の製造のための、非ステロイド性抗炎症薬又はその製剤学的に許容される塩と、グルタチオントリスルフィド又はその製剤学的に許容される塩との組み合わせの使用。
[44]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、[43]に記載の使用。
[45]グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、[43]に記載の使用。
[46]非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、[43]~[45]のいずれかに記載の使用。
必要量のGSSSG及びインドメタシンを電子天秤で秤量し、乳鉢を用いてそれぞれをよくすり潰し、溶媒(0.5%のメチルセルロース(MC)懸濁液)を加えそれぞれ懸濁した。GSSSG単独の投与液は21.2mg/mL(無水換算20mg/mL)、インドメタシン単独の投与液は0.06mg/ml又は0.6mg/mLの濃度になるように作製した。併用投与液は、GSSSGを42.4mg/mL(無水換算40mg/mL)で調製した懸濁液に等量の0.12mg/ml、1.2mg/mLインドメタシン懸濁液を混和して作製した。投与液は2週間分を一括で調製し、投与まで冷蔵、遮光条件で保存した。
Claims (7)
- グルタチオントリスルフィド又はその製剤学的に許容される塩と組み合わせて投与されることを特徴とする、非ステロイド性抗炎症薬又はその製剤学的に許容される塩を含有する炎症性疾患及び/又は疼痛性疾患の予防又は治療薬。
- 非ステロイド性抗炎症薬又はその製剤学的に許容される塩と組み合わせて投与されることを特徴とする、グルタチオントリスルフィド又はその製剤学的に許容される塩を含有する炎症性疾患及び/又は疼痛性疾患の予防又は治療薬。
- グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とが、同時に又は別々に投与される、請求項1又は2に記載の予防又は治療薬。
- グルタチオントリスルフィド又はその製剤学的に許容される塩と、非ステロイド性抗炎症薬又はその製剤学的に許容される塩とを含有する炎症性疾患及び/又は疼痛性疾患の予防又は治療薬。
- グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアミノ酸塩及びグルタチオントリスルフィドのアルカリ金属塩からなる群から選択される少なくとも1種を含む、請求項1~4のいずれか一項に記載の予防又は治療薬。
- グルタチオントリスルフィド又はその製剤学的に許容される塩が、グルタチオントリスルフィド、グルタチオントリスルフィドのアルギニン塩及びグルタチオントリスルフィドのナトリウム塩からなる群から選択される少なくとも1種を含む、請求項1~4のいずれか一項に記載の予防又は治療薬。
- 非ステロイド性抗炎症薬又はその製剤学的に許容される塩が、サリチル酸系非ステロイド性抗炎症薬、プロピオン酸系非ステロイド性抗炎症薬及び酢酸系非ステロイド性抗炎症薬からなる群から選択される少なくとも1種を含む、請求項1~6のいずれか1項に記載の予防又は治療薬。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022579642A JPWO2022168975A1 (ja) | 2021-02-08 | 2022-02-07 | |
CN202280007513.8A CN116615217A (zh) | 2021-02-08 | 2022-02-07 | 炎症性疾病和/或疼痛性疾病的预防或治疗药 |
US18/263,196 US20240082194A1 (en) | 2021-02-08 | 2022-02-07 | Preventive or therapeutic agent for inflammatory disorders and/or pain disorders |
EP22749846.6A EP4272759A1 (en) | 2021-02-08 | 2022-02-07 | Preventive or therapeutic agent for inflammatory disorders and/or pain disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021018177 | 2021-02-08 | ||
JP2021-018177 | 2021-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022168975A1 true WO2022168975A1 (ja) | 2022-08-11 |
Family
ID=82741605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/004692 WO2022168975A1 (ja) | 2021-02-08 | 2022-02-07 | 炎症性疾患及び/又は疼痛性疾患の予防又は治療薬 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240082194A1 (ja) |
EP (1) | EP4272759A1 (ja) |
JP (1) | JPWO2022168975A1 (ja) |
CN (1) | CN116615217A (ja) |
WO (1) | WO2022168975A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024048479A1 (ja) * | 2022-08-30 | 2024-03-07 | 国立大学法人東北大学 | 虚血再灌流傷害抑制 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524087A (ja) * | 1997-04-18 | 2001-11-27 | クリンゲ ファーマ ジーエムビーエイチ | システイニル誘導体を含有する安定化された薬剤 |
WO2017057768A1 (ja) * | 2015-09-30 | 2017-04-06 | 国立大学法人東北大学 | 新規抗酸化眼内灌流液 |
JP2021500384A (ja) | 2017-10-26 | 2021-01-07 | 浙江越甲▲薬▼▲業▼有限公司 | 非ステロイド性抗炎症薬誘導体を含む安定な医薬品組成物 |
-
2022
- 2022-02-07 CN CN202280007513.8A patent/CN116615217A/zh active Pending
- 2022-02-07 EP EP22749846.6A patent/EP4272759A1/en active Pending
- 2022-02-07 US US18/263,196 patent/US20240082194A1/en active Pending
- 2022-02-07 WO PCT/JP2022/004692 patent/WO2022168975A1/ja active Application Filing
- 2022-02-07 JP JP2022579642A patent/JPWO2022168975A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524087A (ja) * | 1997-04-18 | 2001-11-27 | クリンゲ ファーマ ジーエムビーエイチ | システイニル誘導体を含有する安定化された薬剤 |
WO2017057768A1 (ja) * | 2015-09-30 | 2017-04-06 | 国立大学法人東北大学 | 新規抗酸化眼内灌流液 |
JP2021500384A (ja) | 2017-10-26 | 2021-01-07 | 浙江越甲▲薬▼▲業▼有限公司 | 非ステロイド性抗炎症薬誘導体を含む安定な医薬品組成物 |
Non-Patent Citations (5)
Title |
---|
CHENG YU-TING, LU CHI-CHENG, YEN GOW-CHIN: "Phytochemicals enhance antioxidant enzyme expression to protect against NSAID-induced oxidative damage of the gastrointestinal mucosa", MOLECULAR NUTRITION & FOOD RESEARCH, WILEY - VCH VERLAG, WEINHEIM, DE, vol. 61, no. 6, 1 June 2017 (2017-06-01), DE , pages 1600659, XP055955647, ISSN: 1613-4125, DOI: 10.1002/mnfr.201600659 * |
T. AKAIKE ET AL., NATURE COMMUNICATIONS, vol. 8, no. 1, 27 October 2017 (2017-10-27), pages 1177 |
T. IDA ET AL., PNAS, vol. 111, no. 21, 27 May 2014 (2014-05-27), pages 7606 - 7611 |
TAWARAYAMA HIROSHI, SUZUKI NORIYUKI, INOUE-YANAGIMACHI MAKI, HIMORI NORIKO, TSUDA SATORU, SATO KOTA, IDA TOMOAKI, AKAIKE TAKAAKI, : "Glutathione Trisulfide Prevents Lipopolysaccharide-induced Inflammatory Gene Expression in Retinal Pigment Epithelial Cells", OCULAR IMMUNOLOGY AND INFLAMMATION, AEOLUS PRESS, BUREN, NL, vol. ahead-of-print, no. ahead-of-print, 10 December 2020 (2020-12-10), NL , pages 1 - 12, XP009538578, ISSN: 0927-3948, DOI: 10.1080/09273948.2020.1833224 * |
ZHANG TIANLI, TSUTSUKI HIROYASU, ONO KATUSHIKO, AKAIKE TAKAAKI, SAWA TOMOHIRO: "Antioxidative and anti-inflammatory actions of reactive cysteine persulfides", JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION., TOKYO., JP, vol. 68, no. 1, 1 January 2021 (2021-01-01), JP , pages 5 - 8, XP055955646, ISSN: 0912-0009, DOI: 10.3164/jcbn.20-13 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024048479A1 (ja) * | 2022-08-30 | 2024-03-07 | 国立大学法人東北大学 | 虚血再灌流傷害抑制 |
Also Published As
Publication number | Publication date |
---|---|
CN116615217A (zh) | 2023-08-18 |
JPWO2022168975A1 (ja) | 2022-08-11 |
EP4272759A1 (en) | 2023-11-08 |
US20240082194A1 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008534601A5 (ja) | ||
LU88208A1 (fr) | Inhibiteurs mixtes de la no synthase et de la cyclooxygenase, un procédé pour leur préparation et des compositions thérapeutiques les contenant | |
JP2019515884A5 (ja) | ||
WO2016159577A2 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
WO2022168975A1 (ja) | 炎症性疾患及び/又は疼痛性疾患の予防又は治療薬 | |
EA008108B1 (ru) | Комбинация нспвлс и ингибитора pde-4 | |
US20090036516A1 (en) | Compounds for treating metabolic syndrome | |
JP2018526417A (ja) | 高尿酸血症又は痛風の治療又は予防用化合物 | |
AU2007341218B2 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
Innes et al. | Use of non‐steroidal anti‐inflammatory drugs for the treatment of canine osteoarthritis | |
WO2016066851A1 (en) | Combination for the treatment of conditions involving muscular pain | |
WO2009041798A1 (es) | Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. | |
JP6153264B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用 | |
RU2015112586A (ru) | Фармацевтические композиции, содержащие флурбипрофен | |
JP6157214B2 (ja) | 解熱鎮痛薬組成物 | |
JP5997658B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用 | |
US20200022936A1 (en) | Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation | |
EP2548866B1 (en) | New biologically active compound n-[3-(4-nitrophenylamino)-indol-2-ylmethylene]aminoguanidine hydrochloride with anti-inflammatory activity | |
US20060058392A1 (en) | Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase | |
JP6621775B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用 | |
US20080306146A1 (en) | Dosing Regimens for Cox-2 Inhibitor | |
JP5857143B2 (ja) | 抗潰瘍剤組成物 | |
Liu et al. | Enhanced water-soluble derivative of PC407 as a novel potential COX-2 inhibitor injectable formulation | |
WO2011094589A1 (en) | Nonsteroidal antiinflammatory derivatives with decreased toxicity and methods of use | |
WO2010029576A2 (en) | Anti inflammatory compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22749846 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022579642 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280007513.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18263196 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2022749846 Country of ref document: EP Effective date: 20230803 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |